Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
drug eluting-stent, drug-eluting stent · 4 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Cypher Sirolimus-eluting Coronary Stent |
| 2 | ACTIVE_COMPARATOR | Bare-metal stent |
| Name | Type | Description |
|---|---|---|
| drug-eluting stent | DEVICE | Cypher Sirolimus-eluting Coronary Stent |
| bare-metal stent | DEVICE | any bare-metal stent brand |
| drug eluting-stent | DEVICE | PCI |
Inclusion Criteria: 1. Have prolonged, continuous (lasting at least 20 minutes) chest pain despite administration of nitrates and onset within 12 hours of randomization, and one of the following: 1. ST segment elevation \>=1mm in standard leads and \>=2mm in 2 or more contiguous precordial lead...
Top 8 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Ziltivekimab |
| Novartis AG Sponsored ADR | NVS | 4 | PHASE3 | Inclisiran |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| Viatris, Inc. | VTRS | 1 | PHASE3 | Selatogrel |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 1 | - | alirocumab |
The drug-eluting stent is used to treat coronary artery disease and peripheral artery disease. It is a stent designed to release medication to help keep arteries open. Clinical studies have evaluated it in patients with conditions such as coronary artery disease and peripheral artery disease, including those with de novo artery lesions and bifurcation lesions.
Cardinal Health, Inc. (NYSE: CAH) is the developer of the drug-eluting stent. The company has sponsored clinical trials of the stent for treating coronary artery disease and peripheral artery disease. These trials have been conducted in multiple countries, including France, Germany, and Italy.
The drug-eluting stent is in Phase 3 clinical development for coronary artery disease and peripheral artery disease. It has completed four clinical trials, including Phase 3 studies. The stent is investigational and not yet approved for commercial use based on the available clinical trial data.
The drug-eluting stent has completed four clinical trials. NCT00232830 is a Phase 3 study in coronary artery disease with 715 participants. NCT00232869 is a Phase 2 study in peripheral artery disease with 93 participants. NCT00234455 is a Phase 2 study in coronary artery disease with 86 participants. NCT00381420 is a Phase 3 study in coronary artery disease with 100 participants.
The drug-eluting stent is evaluated in clinical trials under different names, including the Cypher sirolimus-eluting stent and the BX Velocity stent. One completed study, NCT00234455, specifically investigated the Cypher sirolimus-eluting stent for treating bifurcation lesions in coronary artery disease. Another study, NCT00381420, examined the BX Velocity stent for de novo artery lesions.
The drug-eluting stent treats coronary artery disease and peripheral artery disease. Clinical trials have enrolled patients with these conditions, including those with acute myocardial infarction, superficial femoral artery disease, bifurcation lesions, and de novo artery lesions. The studies were randomized, double-blind, and controlled, with a total enrollment of 1,508 participants across all trials.